NEO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 410.11 -- higher than 91.11% of US-listed equities with positive expected earnings growth.
With a price/sales ratio of 13.78, Neogenomics Inc has a higher such ratio than 86.82% of stocks in our set.
In terms of twelve month growth in earnings before interest and taxes, Neogenomics Inc is reporting a growth rate of -288.73%; that's higher than only 6.93% of US stocks.
Stocks with similar financial metrics, market capitalization, and price volatility to Neogenomics Inc are VSAT, PRGO, THR, PEN, and QBAK.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.
NeoGenomics (NEO) has priced concurrent public offerings of (a) 4,081,632 common shares at $49.00/share for gross proceeds of $200M and (b) $300M aggregate principal amount of its 0.25% convertible senior notes due 2028.Underwriters' over-allotment is an additional 612,244 shares and $45M of the notes. The initial conversion rate is 15.1172...
Investment Thesis We are long NeoGenomics (NEO) shares and hold a bullish long-term sentiment based on fundamental momentum, key differentiators within the portfolio mix and acquisition success over the previous periods for the company. NEO sits at the tip of the spear for our high-quality-growth-at-a-reasonable-price ("HQ-GARP") list and offers a...